Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348930 · ClinicalTrials.gov registry record · Phase 2
Tolcapone in Obsessive Compulsive Disorder
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03348930 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 20 participants.
The verdict
NCT03348930, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The proposed study will consist of a 5-week double-blind cross-over study trial of tolcapone in 20 people (ages 18-65). The study will be divided into an initial 2 week phase and a second 2 week phase, with one of the 2 week phases consisting of active treatment with tolcapone, and the other 2 week phase consisting of inactive placebo treatment. There will be a one-week wash-out phase between the 2-week treatment phases. Participants will be randomized to receive either tolcapone or placebo during the first 2 week phase on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.
Interventions
- DRUG Tolcapone 200 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2020-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03348930
The ClinicalTrials.gov registry entry for NCT03348930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tolcapone 200 MG is the first listed.
NCT03348930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03348930 about?
NCT03348930 is a clinical study titled "Tolcapone in Obsessive Compulsive Disorder". The proposed study will consist of a 5-week double-blind cross-over study trial of tolcapone in 20 people (ages 18-65). The study will be divided into an initial 2 week phase and a second 2 week phase, with one of the 2 week phases consisting of active treatment with tolcapone, and the other 2 week ...
What is the current status of trial NCT03348930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-03-20. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT03348930?
The interventions under investigation include: Tolcapone 200 MG (DRUG).
Who is sponsoring clinical trial NCT03348930?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.